Resource Search

Results: 330

The EPP Expert Board members read - and select - for you the ‘must’ read books, articles and whitepapers for pricing practitioners.  
EPP Connect&More is another great source for pricing professionals, managed by a team of industry contributors. 
* Sign-up to receive the free monthly EPP Connect&More : here
* Some content in the EPP Content database is reserved for EPP Members only ;  sign-up : here


Pricing Maturity Playbook - Crossing the pricing chasm

  • Author(s): Pol Vanaerde
  • Uploaded on: 08/01/2021
  • Content Type: Articles

How Does the Biden Administration Want to ‘Take on Pharma?’

  • Democratic President-elect Joe Biden and his administration are poised to take the reins from President Donald Trump, who had just begun to more stringently address prescription drug prices in the U.S. via Executive Orders (EOs) aimed at introducing an American version of reference pricing.
  • Throughout his campaign, Biden has promised to expand access to health care through the “BidenPlan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,”while “taking on big pharma” and reining in “runaway” drug prices.
  • Biden has also announced intentions to set up a government-run, Institute for Clinical and Economic Review (ICER) -style Health Technology Assessment (HTA) body, as ICER is currently an autonomous body to the U.S. government
  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 16/12/2020
  • Content Type: Articles

Do Germany's New Hemophilia Regulations Have Wider-reaching Implications?

In July 2019, the Drug Safety and Supply Law (GSAV) was passed by Germany’s Higher Chamber of Parliament, bringing about substantial changes to Germany’s health policy.

Since the GSAV’s implementation in August of this year, the distribution, and consequently the pricing of hemophilia treatments in Germany have been subject to more regulation under the law.

In addition, the manufacturer’s ability to distribute directly to doctors and hospitals, avoiding the pharmacy distribution channel, was officially withdrawn, thereby allowing patients to receive their hemophilia products from regular pharmacies and ultimately meaning that manufacturers had to report their confidential sales prices to physicians.

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 23/11/2020
  • Content Type: Articles

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality.

The first safety trials in humans started as early as March, due to various expedited clinical development processes in place around the globe that promised to bring a vaccine to fruition as quickly as 12 to 18 months from the outbreak of the pandemic—an unprecedented time frame that was quick to spark a reaction from critics.

But now, as the reality of a commercialized SARS-CoV-2 vaccine becomes closer every day, countries the world are over are starting to ink deals with various front running companies in order to ensure supply for their citizens when the time comes.

Dedicating budget and resources to finding and accessing a COVID-19 vaccine means that there will have to be trade-offs in other areas of healthcare, which could trickle down for years to come, so it’s important that government bodies and organizations get the best deal possible.

Some companies have already proposed potential vaccine prices, throwing out ballpark figures of anything from around $4 to $72 for a dose, calling into question how much we actually end up paying for a vaccine. 

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 14/09/2020
  • Content Type: Articles

Italy tackles HTA, pricing and reimbursment reforms

In July, new legislation set to overhaul the way pharmaceuticals are priced in Italy was finally implemented, following an announcement that dates all the way back to August 2019. The provision, which was signed by then Ministers Giulia Grillo (Health) and Giovanni Tria (Economy), has rolled out new criteria and methods by which the Italian Medicines Agency (AIFA) determines, via negotiation, the prices of drugs reimbursed by the national health service (SSN).

 

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 16/10/2020
  • Content Type: Articles

EPP Thought Leadership Series 1/2020

Edition 1/2020How restaurants and food service companies can boost their revenues and occupancy, with the effective use of data analytics

Food Away From Home (AFH) sales in the European Union have reached almost € 600 billion per year; figures that increase year over year and that represent approximately 7-7.5% of the overall European expenses.

The industry is rushing, bringing new players in the field, facilitating consolidation, showing a fostering trend of internationalization similar to the one already experimented in the fashion industry. But with millions of customers eating out or ordering online every day, where does the industry stand in the use of data, to support its growth?

This paper aims to define a possible project plan that companies in the food industry can follow to deliver immediate revenue benefits to their business and enable their companies to compete in a more and more sophisticated battlefield.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions

  • Author(s): Maiora Solutions
  • Uploaded on: 03/01/2020
  • Content Type: Articles

Commercial excellence amid COVID-19 and after

How are companies influenced by the current crisis and what are their most common commercial challenges? How can commercial excellence play a crucial role in defining the right actions to mitigate and avoid negative impacts on bottom line results?

  • Author(s): Marc Abels & Maarten Moreels
  • Uploaded on: 24/04/2020
  • Content Type: Articles

The digital pricing journey for SAP users

14th EPP European & Global Pricing Forum

  • Author(s): Walter Wijnands - SPOSEA
  • Uploaded on: 23/12/2019
  • Content Type: Forum presentations

EPP Thought Leadership Series 3/2019

Edition 3/2019: How do we pay for a cure? The risks and rewards of innovative payment schemes

Setting drug prices is a high-stakes endeavor, and that is especially true for the latest round of gene and curative products coming to market in Europe. Drugmakers need to consider several factors that can help them set their product prices appropriately, including the risk of recurrence/ relapse, differences in efficacy among cures, and comparators, including full lifecycle costs of a disease and the burden of health economic costs on budgets. They also need to design innovative payment models that will be attractive to health systems facing increased budgetary pressures as more gene and curative products enter the market. This includes outcomes- and performance-based
schemes, which have gained momentum across Europe. However, drugmakers need to be cautious because such models could leave them vulnerable to “known unknowns,” including whether a cure can be sustained throughout a patient’s lifetime, given the lack of long-term data.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions

  • Author(s): Lena Chatchatrian
  • Uploaded on: 03/01/2020
  • Content Type: Articles

Real Case Study of Implementing Dynamic Pricing

14th EPP European & Global Pricing Forum

  • Author(s): Varun Tyagi - Movinga
  • Uploaded on: 23/12/2019
  • Content Type: Forum presentations
Cron Job Starts